Nicox Sa EUR Ord (NICXF) 2.7300 $NICXF
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma
Nicox launches commercial operations in Germany
GlobeNewswire - Mon Jun 30, 12:37AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch of its German operations. Nicox is now promoting and selling Xailin(TM), a new range of tear lubricants for relief of dry eye symptoms (medical devices), and AdenoPlus, an in vitro diagnostic medical device (IVDMD) to help the differential diagnosis of acute conjunctivitis, through its own sales force in Germany.
Nicox and Sequenom announce the launch of expanded access to RetnaGene(TM) test portfolio in the U.S.
PR Newswire - Thu Jun 19, 6:00AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration (AMD).
Duchenne Muscular Dystrophy - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vbwmb/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Sanofi - Eli Lilly and Company - Daiichi Sankyo Company, Limited - Nippon Shinyaku Co., Ltd. - Sarepta Therapeutics, Inc. - NicOx S.A. - Galapagos NV - Summit Corporation plc - Santhera Pharmaceuticals Holding AG - Shenzhen Beike Biotechnology Co., Ltd. - Italfarmaco S.p.A. - Prosensa Holding BV - Catabasis Pharmaceuticals, Inc. - Nobelpharma Co., Ltd. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - N-Gene Research Laboratories, Inc. - Asklepios BioPharmaceutical, Inc. - Genethon - miRagen Therapeutics, Inc. - Prosensa Therapeutics B.V. - EryDel SPA - Myomics, Inc. - Prothelia, Inc. - ReveraGen BioPharma, Inc. - Retrophin, LLC For more information visit http://www.researchandmarkets.com/research/3v...e_muscular
CORRECTED RELEASE - Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm(R) in Italy
GlobeNewswire - Fri May 30, 12:35AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today issued a revised version of the press release dated May 28, 2014, to correct the number of newly issued Nicox shares to be paid to Fin Posillipo SPA in relation to the extension of the Cationorm distribution agreement in Italy. The earn-out payment will be made in the form of 821,996 newly issued Nicox shares (not 823,483 as previously stated).
Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm(R) in Italy
GlobeNewswire - Wed May 28, 12:37AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announces that its wholly-owned Italian subsidiary Eupharmed has entered into an exclusive agreement with Santen SAS, enabling Eupharmed to continue to distribute Cationorm in Italy.
Nicox 2013 Financial Results and Business Update
GlobeNewswire - Wed Apr 02, 12:41AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today announced its financial results for the year ended December 31, 2013, and provided an overview of its activities.
Nicox launches AdenoPlus(R) and Xailin(TM) dry eye product range in Europe
GlobeNewswire - Mon Mar 17, 1:35AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today announced the European launch of Xailin(TM), a new range of tear lubricants (medical devices) for relief of dry eye symptoms, and of AdenoPlus, an in vitro diagnostic medical device (IVDMD) to help the differential diagnosis of acute conjunctivitis. Nicox is now promoting and selling the first Xailin(TM) products and AdenoPlus through its own sales force in the UK, Italy, Spain and France. Commercial operations in Germany are expected to begin in the second quarter of 2014.
Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
GlobeNewswire - Fri Feb 14, 12:34AM CST
Nicox S.A. (NYSE Euronext Paris: COX) today announced its decision to re-focus naproxcinod development efforts. Nicox has granted an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of naproxcinod and of next generation nitric oxide (NO)- donors outside the ophthalmology area. The evaluation will be entirely funded by this partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right, should the results of the evaluation be satisfactory to the partner, to invest at the end of the evaluation period in naproxcinod and next generation NO-donors outside ophthalmology through an independent structure. Nicox will not pursue any other development activities or discussions with third parties related to naproxcinod.
Seborrhea - Pipeline Review, H2 2013 Report
M2 - Fri Jan 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/g2tt6p/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H2 2013" report to their offering. 'Seborrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Seborrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seborrhea. Scope - A snapshot of the global therapeutic scenario for Seborrhea. - A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Seborrhea pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Valeant Pharmaceuticals International, Inc. NicOx S.A. Xenon Pharmaceuticals Inc. Maruho Co., Ltd. Vyome Biosciences Pvt Ltd Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/g2tt6p/seborrhea About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
PR Newswire - Thu Jan 16, 4:59PM CST
Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene(TM) AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjo(TM), an advanced diagnostic panel for the early detection of Sjogren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eczema - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twqxc/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2013" report to their offering. 'Eczema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eczema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eczema. Scope - A snapshot of the global therapeutic scenario for Eczema. - A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eczema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Merck & Co., Inc. Taisho Pharmaceutical Co., Ltd. Novartis AG Chugai Pharmaceutical Co. Ltd Dr. Reddy's Laboratories Limited Eisai Co., Ltd. Galderma S.A. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Nippon Shinyaku Co., Ltd. Sun Pharmaceutical Industries Limited Sandoz Inc. Bayer AG AlbireoPharma Almirall, S.A. NicOx SA Regeneron Pharmaceuticals, Inc. Array BioPharma Inc. ProMetic Life Sciences Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7t...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation
Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis
NiCOX FEATURED ARTICLE: Presentations at ARVO 2013 Annual Meeting
Marketwire - Mon May 13, 6:36AM CDT
NiCOX WEB NEWS: FEATURED ARTICLE
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018
M2 - Wed Jul 02, 2:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zpvs7l/global_glaucoma) has announced the addition of the "Global Glaucoma Therapeutics Market Forecasts & Opportunities, 2018" report to their offering. Glaucoma is a disease of the eye in which fluid pressure within the eye increases. If left untreated the patient may lose vision and even become blind. The exact etiology of optic nerve damage due to glaucoma is not fully known, but involves mechanical compression and/or decreased blood flow in the optic nerve. Based on whether the cause of the disease is unknown or known, glaucoma is divided into two types, open angle and closed angle glaucoma. Five main classes of medical treatment are currently used to lower intraocular pressure: prostaglandins, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, and fixed dose combinations. The Global Glaucoma Therapeutics market can be divided into five segments: Prostaglandins, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, and Fixed Dose Combinations. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Glaucoma Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Key Vendors - Allergan Inc. - Merck & Co. Inc. - Novartis AG - Pfizer Inc. Other Prominent Vendors - Acadia Pharmaceuticals Inc. - AC Immune SA - Acorn Biomedical Inc. - Advanced Cell Technology Inc. - Aerie Pharmaceuticals Inc. - Carl Zeiss Meditec Inc. - Falcon Pharmaceuticals Ltd. - Inotek Pharmaceuticals Corp. - Lexicon Pharmaceuticals Inc. - Neurotech Pharmaceuticals Inc. - NicOx SA - Otsuka Holdings Co. Ltd. - Phytopharm plc - Santen Pharmaceuticals Co. Ltd. - Senju Pharmaceutical Co. Ltd. - SIFI SpA - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Pipeline Snapshot - Rate of Incidence and Prevalence - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/zp...l_glaucoma
Nicox launches commercial operations in Germany
GlobeNewswire - Mon Jun 30, 12:37AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced the launch of its German operations. Nicox is now promoting and selling Xailin(TM), a new range of tear lubricants for relief of dry eye symptoms (medical devices), and AdenoPlus, an in vitro diagnostic medical device (IVDMD) to help the differential diagnosis of acute conjunctivitis, through its own sales force in Germany.
Nicox and Sequenom announce the launch of expanded access to RetnaGene(TM) test portfolio in the U.S.
PR Newswire - Thu Jun 19, 6:00AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, and Sequenom, Inc. (NASDAQ:SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration (AMD).
Duchenne Muscular Dystrophy - Pipeline Review, H1 2014
M2 - Wed Jun 11, 5:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vbwmb/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Duchenne Muscular Dystrophy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - Sanofi - Eli Lilly and Company - Daiichi Sankyo Company, Limited - Nippon Shinyaku Co., Ltd. - Sarepta Therapeutics, Inc. - NicOx S.A. - Galapagos NV - Summit Corporation plc - Santhera Pharmaceuticals Holding AG - Shenzhen Beike Biotechnology Co., Ltd. - Italfarmaco S.p.A. - Prosensa Holding BV - Catabasis Pharmaceuticals, Inc. - Nobelpharma Co., Ltd. - PTC Therapeutics, Inc. - Fate Therapeutics, Inc. - N-Gene Research Laboratories, Inc. - Asklepios BioPharmaceutical, Inc. - Genethon - miRagen Therapeutics, Inc. - Prosensa Therapeutics B.V. - EryDel SPA - Myomics, Inc. - Prothelia, Inc. - ReveraGen BioPharma, Inc. - Retrophin, LLC For more information visit http://www.researchandmarkets.com/research/3v...e_muscular
CORRECTED RELEASE - Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm(R) in Italy
GlobeNewswire - Fri May 30, 12:35AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today issued a revised version of the press release dated May 28, 2014, to correct the number of newly issued Nicox shares to be paid to Fin Posillipo SPA in relation to the extension of the Cationorm distribution agreement in Italy. The earn-out payment will be made in the form of 821,996 newly issued Nicox shares (not 823,483 as previously stated).
Nicox: Santen grants Eupharmed extension of exclusive rights to distribute Cationorm(R) in Italy
GlobeNewswire - Wed May 28, 12:37AM CDT
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announces that its wholly-owned Italian subsidiary Eupharmed has entered into an exclusive agreement with Santen SAS, enabling Eupharmed to continue to distribute Cationorm in Italy.
Nicox 2013 Financial Results and Business Update
GlobeNewswire - Wed Apr 02, 12:41AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today announced its financial results for the year ended December 31, 2013, and provided an overview of its activities.
Nicox launches AdenoPlus(R) and Xailin(TM) dry eye product range in Europe
GlobeNewswire - Mon Mar 17, 1:35AM CDT
Nicox S.A. (NYSE Euronext Paris: COX) today announced the European launch of Xailin(TM), a new range of tear lubricants (medical devices) for relief of dry eye symptoms, and of AdenoPlus, an in vitro diagnostic medical device (IVDMD) to help the differential diagnosis of acute conjunctivitis. Nicox is now promoting and selling the first Xailin(TM) products and AdenoPlus through its own sales force in the UK, Italy, Spain and France. Commercial operations in Germany are expected to begin in the second quarter of 2014.
Nicox to re-focus naproxcinod on Duchenne muscular dystrophy
GlobeNewswire - Fri Feb 14, 12:34AM CST
Nicox S.A. (NYSE Euronext Paris: COX) today announced its decision to re-focus naproxcinod development efforts. Nicox has granted an undisclosed financial partner the right to enter into a period of exclusive evaluation to assess the potential development of naproxcinod and of next generation nitric oxide (NO)- donors outside the ophthalmology area. The evaluation will be entirely funded by this partner and will be focused initially on Duchenne muscular dystrophy (DMD). Nicox has granted the undisclosed partner the exclusive right, should the results of the evaluation be satisfactory to the partner, to invest at the end of the evaluation period in naproxcinod and next generation NO-donors outside ophthalmology through an independent structure. Nicox will not pursue any other development activities or discussions with third parties related to naproxcinod.
Seborrhea - Pipeline Review, H2 2013 Report
M2 - Fri Jan 24, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/g2tt6p/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H2 2013" report to their offering. 'Seborrhea - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Seborrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Seborrhea. Scope - A snapshot of the global therapeutic scenario for Seborrhea. - A review of the Seborrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Seborrhea pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Valeant Pharmaceuticals International, Inc. NicOx S.A. Xenon Pharmaceuticals Inc. Maruho Co., Ltd. Vyome Biosciences Pvt Ltd Biomar Microbial Technologies For more information visit http://www.researchandmarkets.com/research/g2tt6p/seborrhea About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Sequenom Laboratories grants Nicox exclusive promotion and marketing rights for its RetnaGene(TM) AMD test in North America
PR Newswire - Thu Jan 16, 4:59PM CST
Nicox S.A. (NYSE Euronext Paris: COX), and Sequenom, Inc. (NASDAQ:SQNM), today announced that their affiliate companies (Nicox Inc. and Sequenom Laboratories) have entered into an exclusive agreement in the age-related macular degeneration (AMD) field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene(TM) AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within 2, 5 and 10 years. The RetnaGene AMD test will be promoted by the same Nicox U.S. sales force which recently launched Sjo(TM), an advanced diagnostic panel for the early detection of Sjogren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014.
Global Pulmonary Fibrosis Pipeline Review Report - H2 2013 Edition Now Available
M2 - Tue Dec 17, 10:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/cqb72k/pulmonary) has announced the addition of the "Pulmonary Fibrosis - Pipeline Review, H2 2013" report to their offering. 'Pulmonary Fibrosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis. Scope - A snapshot of the global therapeutic scenario for Pulmonary Fibrosis. - A review of the Pulmonary Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Pulmonary Fibrosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Pulmonary Fibrosis Therapeutics Development - Eli Lilly and Company - Lpath, Inc. - Mesoblast Ltd - NicOx SA - Oncothyreon Inc - Pharmaxis Ltd. - Paloma Pharmaceuticals, Inc. - Digna Biotech, S.L. - Aquinox Pharmaceuticals Inc. - Angion Biomedica Corp. - Centocor Ortho Biotech, Inc. - Fibrotech Therapeutics Pty. Ltd. - FCB-Pharmicell Co.,Ltd. - Clarassance, Inc. Drug Profiles - Lpathomab - P-17 - AZX-100 - PX-866 - STNM-04 - P-529 - AQX-1125 - Btx-201 - GR-MD-02 - ICG-001 - CG-1011 - ANG-3298 - C-201 - Galectin-3 Inhibitors - SDP-051 - FT-011 - CT-140 - PDE-4A4 Inhibitors - NCX-466 - MC-1575 - Lungcellgram - CpG Oligonucleotides - PXS-5033-A For more information visit http://www.researchandmarkets.com/research/cqb72k/pulmonary
Glaucoma - Pipeline Review, H2 2013
M2 - Mon Sep 09, 5:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l2kcjq/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2013" report to their offering. 'Glaucoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. Scope - A snapshot of the global therapeutic scenario for Glaucoma. - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Glaucoma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Alcon, Inc. F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. QLT Inc. Advanced Cell Technology, Inc. Quark Pharmaceuticals, Inc. Santen Pharmaceutical Co., Ltd. Oxford BioMedica plc Sylentis RetinaPharma Technologies, Inc. Novagali Pharma SA Kowa Company, Ltd. Merz GmbH & Co. KGaA Ono Pharmaceutical Co., Ltd. Pfizer Inc. Sun Pharmaceutical Industries Limited InSite Vision Incorporated Can-Fite BioPharma Ltd. NicOx SA ACADIA Pharmaceuticals Inc. Lexicon Pharmaceuticals, Inc. and many more... For more information visit http://www.researchandmarkets.com/research/l2kcjq/glaucoma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Osteoarthritis - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nkkfb7/osteoarthritis) has announced the addition of the "Osteoarthritis - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis. - A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Johnson & Johnson Osiris Therapeutics, Inc. Seikagaku Corporation Sanofi-Aventis Ablynx TiGenix NV Novartis AG Astellas Pharma Inc. Chong Kun Dang Pharmaceutical Chugai Pharmaceutical Co. Ltd Pfizer Inc. Menarini Group Merck KGaA Bone Medical Limited Addex Pharmaceuticals Can-Fite BioPharma Ltd. Medivir AB Mesoblast Ltd Calzada Limited NicOx SA and many more... For more information visit http://www.researchandmarkets.com/research/nk...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Eczema - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7twqxc/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2013" report to their offering. 'Eczema - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Eczema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eczema. Scope - A snapshot of the global therapeutic scenario for Eczema. - A review of the Eczema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Eczema pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Bristol-Myers Squibb Company GlaxoSmithKline plc Daiichi Sankyo Company, Ltd Merck & Co., Inc. Taisho Pharmaceutical Co., Ltd. Novartis AG Chugai Pharmaceutical Co. Ltd Dr. Reddy's Laboratories Limited Eisai Co., Ltd. Galderma S.A. LEO Pharma A/S Mitsubishi Tanabe Pharma Corporation Nippon Shinyaku Co., Ltd. Sun Pharmaceutical Industries Limited Sandoz Inc. Bayer AG AlbireoPharma Almirall, S.A. NicOx SA Regeneron Pharmaceuticals, Inc. Array BioPharma Inc. ProMetic Life Sciences Inc. and many more... For more information visit http://www.researchandmarkets.com/research/7t...a_pipeline About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Skin Inflammation - Pipeline Review, H2 2012
M2 - Wed Jul 31, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cclx3v/skin_inflammation) has announced the addition of the "Skin Inflammation - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the Skin Inflammation therapeutic pipeline. This report provides information on the therapeutic development for Skin Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin Inflammation. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Skin Inflammation Overview Therapeutics Development An Overview of Pipeline Products for Skin Inflammation Companies Involved in Skin Inflammation Therapeutics Development Skin Inflammation - Therapeutics Assessment Assessment by Monotherapy Products Assessment by Combination Products Assessment by Route of Administration Assessment by Molecule Type Drug Profiles Skin Inflammation Therapeutics - Drug Profile Updates Skin Inflammation Therapeutics - Discontinued Products Skin Inflammation Therapeutics - Dormant Products Skin Inflammation - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned - APEIRON Biologics AG - Action Pharma A/S - Almirall, S.A - Amgen Inc - AnGes MG, Inc - AnaMar Medical AB - Anacor Pharmaceuticals, Inc - Array BioPharma Inc - Asubio Pharmaceuticals, Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - CREABILIS Therapeutics S.r.l. - Celtic Pharmaceutical Holdings L.P - Clarassance, Inc - Companies Involved in Skin Inflammation Therapeutics Development - Cutanea Life Sciences - Daiichi Sankyo Company, Ltd - Deciphera Pharmaceuticals, LLC - EMS S.A - Eisai Co., Ltd - Fougera - Galderma S.A. - GlaxoSmithKline plc - Hanall Pharmaceutical Co., Ltd - Hawthorn Pharmaceuticals, Inc - Hygeia Therapeutics, Inc - IMMD Inc. - JADO Technologies GmbH. - LEO Pharma A/S - MIKA Pharma GmbH - Maruho Co.,Ltd - MedImmune LLC - Melior Discovery, Inc. - Morphotek, Inc - Morria Biopharmaceuticals Plc - NKT Therapeutics, Inc - NicOx SA - Nippon Shinyaku Co., Ltd - Novartis AG - Nuvo Research Inc. - Oxagen Limited - Palau Pharma S.A - Paloma Pharmaceuticals, Inc - Pharis Biotec GmbH - Phytopharm Plc - ProMetic Life Sciences Inc - Provectus Pharmaceuticals, Inc - Proximagen Neuroscience plc - R-Tech Ueno, Ltd - Regeneron Pharmaceuticals, Inc - Respiratorius AB - SARcode Corporation - SWITCH Biotech LLC - Stiefel Laboratories, Inc - Summit Corporation plc - Syntrix Biosystems, Inc - Viromed Co., Ltd - Welichem Biotech Inc For more information visit http://www.researchandmarkets.com/research/cc...flammation
Dermatitis - Pipeline Review, H2 2012
M2 - Fri Jul 26, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrd9dn/dermatitis) has announced the addition of the "Dermatitis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. The data is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Dermatitis. - A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Dermatitis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction REPORT COVERAGE Dermatitis Overview Therapeutics Development An Overview of Pipeline Products for Dermatitis Dermatitis Therapeutics under Development by Companies Dermatitis Therapeutics under Investigation by Universities/Institutes Late Stage Products Comparative Analysis Mid Clinical Stage Products Comparative Analysis Early Clinical Stage Products Comparative Analysis Discovery and Pre-Clinical Stage Products Comparative Analysis Dermatitis Therapeutics - Products under Development by Companies Dermatitis Therapeutics - Products under Investigation by Universities/Institutes Companies Involved in Dermatitis Therapeutics Development Drug Profiles Dermatitis Therapeutics - Drug Profile Updates Dermatitis Therapeutics - Discontinued Products Dermatitis Therapeutics - Dormant Products Dermatitis - Product Development Milestones Featured News & Press Releases Appendix Companies Mentioned: (58) Including: - Almirall, S.A - Amgen Inc - AnGes MG - Array BioPharma Inc - Bayer HealthCare AG - Bristol-Myers Squibb Company - Daiichi Sankyo Company - Eisai Co - Galderma S.A - GlaxoSmithKline - Hanall Pharmaceutical Co - LEO Pharma A/S - MedImmune LLC - NicOx SA - Nippon Shinyaku Co - Novartis AG - Nuvo Research Inc - Phytopharm - ProMetic Life Sciences Inc - Provectus Pharmaceuticals - Proximagen Neuroscience - R-Tech Ueno - Regeneron Pharmaceuticals, Inc - Stiefel Laboratories - Summit Corporation For more information visit http://www.researchandmarkets.com/research/hrd9dn/dermatitis
NiCOX FEATURED ARTICLE: Presentations at ARVO 2013 Annual Meeting
Marketwire - Mon May 13, 6:36AM CDT
NiCOX WEB NEWS: FEATURED ARTICLE
